8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Nov 12, 2025·SEC
Cryo-Cell International, Inc.(CCEL)Earnings, Financials & Key Ratios
CCEL•NASDAQ
$3.17
Price updated Jun 27, 2026
AboutCryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.Show more
- Revenue$32M-1.3%
- EBITDA$6M+56.7%
- Net Income-$2M-704.2%
- EPS (Diluted)-0.30-700.0%
- Gross Margin76.63%+2.0%
- EBITDA Margin19.67%+58.7%
- Operating Margin15.34%+41.0%
- Net Margin-7.7%-712.2%
CCEL Price & Volume
Cryo-Cell International, Inc. (CCEL) stock price & volume — 10-year historical chart
Loading chart...
Revenue Stagnation Challenges Cryo-Cell Financial Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Strained
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Critical liquidity and insolvency
Key Thesis Takeaways
- Cryo-Cell International faces a precarious outlook characterized by a 3.6% year-over-year revenue decline and a negative equity position of $18.4 million as of 2026Q1.
- While the company maintains resilient gross margins averaging 76%, its reliance on volatile SG&A spending and limited cash reserves of $249,700 creates significant operational risk.
- Investors should monitor the company's ability to manage its $9.4 million in deferred revenue obligations against its current ratio of 0.62, which suggests limited flexibility to fund future clinical-stage growth.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $249,700 and a negative equity base of $18.4 million, presents an elevated risk of insolvency.
CCEL Growth Metrics
Cryo-Cell International, Inc. (CCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.11%
5 Years0.27%
3 Years1.33%
TTM-2.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2170.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3300%
Return on Capital
10 Years15.22%
5 Years2.42%
3 Years-2.99%
Last Year11.39%
Peers Comparison
Key metrics vs top competitors for Cryo-Cell International, Inc. (CCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.17 | $25.53M | -10.57 | -1.31% | -7.7% | — | 12.63% | |
| $46.23 | $2.36B | 144.47 | 16.45% | 7.35% | 6.41% | — | |
| $28.67 | $1.4B | -114.68 | 16.97% | -10.52% | -2.91% | — | |
| $18.76 | $1.46B | -2.79 | 1.53% | -30.15% | -47.65% | — | |
| $4.46 | $320.97M | -4.74 | -38.1% | -61.93% | -15.09% | — | |
| $261.91 | $37.51B | -172.31 | 35.9% | -9.05% | -15.13% | — |
Compare CCEL vs Peers
Cryo-Cell International, Inc. (CCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CCEL SEC Filings & Documents
Cryo-Cell International, Inc. (CCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CCEL Frequently Asked Questions
Cryo-Cell International, Inc. (CCEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cryo-Cell International, Inc.'s revenue?
Cryo-Cell International, Inc. (CCEL) reported $31.3M in revenue for fiscal year 2025. This represents a 1059% increase from $2.7M in 1996.
How fast is Cryo-Cell International, Inc. growing?
Cryo-Cell International, Inc. (CCEL) saw revenue decline by 1.3% over the past year.
Is CCEL profitable?
Cryo-Cell International, Inc. (CCEL) reported a net loss of $2.7M for fiscal year 2025.
Dividend & Returns
Does CCEL pay dividends?
Yes, Cryo-Cell International, Inc. (CCEL) pays a dividend with a yield of 12.63%. This makes it attractive for income-focused investors.
What is Cryo-Cell International, Inc.'s free cash flow?
Cryo-Cell International, Inc. (CCEL) generated $4.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.